Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension

Publications

Data source publications

• Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry
• Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)
• Incidence and prevalence of pulmonary arterial hypertension in Germany
• Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum
• Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
• Risk assessment in pulmonary arterial hypertension
• The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry
• Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry
• Risk stratification in pulmonary arterial hypertension using Bayesian analysis
• Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry
• COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
• Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)
• Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis
• Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis
• Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis
• Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry
• Performance of the ESC/ERS 4-strata risk stratification model for pulmonary arterial hypertension with missing variables
• Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis
• Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis
• Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis